Skip to main content

Table 2 Hazard ratio (HR) and 95 % CI for the association between automated KI67 score and 10-year BCSS in partially and fully adjusted models: analysis stratified overall and according to ER, nodal status and other immunohistochemical markers (N = 8088 patients)

From: Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups

   

Partially adjusteda

Fully adjustedb

Patients (N)

Deaths (N)

HR (95 % CI)

P value

HR (95 % CI)

P value

All cancers

 Low KI67

6093

1030

1.00 (referent)

 

1.00 (referent)

 

 High KI67

1995

371

2.32 (1.79–3.00)

6.34 × 10−11

1.47 (1.13–1.92)

0.004

T c

  

0.89 (0.84–0.94)

3.20 × 10−5

0.93 (0.87–0.98)

0.010

ER-positive

 Low KI67

4379

615

1.00 (referent)

 

1.00 (referent)

 

 High KI67

1141

166

2.47 (1.63–3.72)

8.45 × 10−6

1.96 (1.31–2.93)

0.001

T

  

0.88 (0.81–0.96)

0.003

0.89 (0.82–0.97)

0.006

ER-negative

 Low KI67

1271

320

1.00 (referent)

 

1.00 (referent)

 

 High KI67

778

188

1.38 (0.97–1.97)

0.072

1.23 (0.86–1.77)

0.248

T

  

0.94 (0.86–1.02)

0.155

0.94 (0.87–1.03)

0.199

ER-positive/node-positive

 Low KI67

1550

350

1.00 (referent)

 

1.00 (referent)

 

 High KI67

408

94

2.22 (1.31–3.77)

0.003

1.74 (1.05–2.86)

0.031

T

  

0.91 (0.82–0.99)

0.044

0.91 (0.82–1.01)

0.075

ER-positive/node-negative

 Low KI67

2399

205

1.00 (referent)

 

1.00 (referent)

 

 High KI67

561

55

3.17 (1.43–6.99)

0.004

2.47 (1.16–5.27)

0.019

T

  

0.84 (0.71–0.98)

0.034

0.86 (0.73–0.99)

0.048

HRP/HER2–

 Low KI67

3332

462

1.00 (referent)

 

1.00 (referent)

 

 High KI67

831

114

1.69 (1.26–2.27)

2.42 × 10−4

1.49 (1.10–2.00)

0.009

T

  

0.94 (0.90–0.98)

0.004

0.94 (0.90–0.98)

0.004

HRP/HER2+

 Low KI67

421

82

1.00 (referent)

 

1.00 (referent)

 

 High KI67

157

36

1.96 (1.28–3.00)

9.70 × 10−4

1.59 (1.03–2.45)

0.035

T

  

0.94 (0.90–0.98)

0.004

0.94 (0.90–0.98)

0.004

HRN/HER2– (triple-negative)

 Low kI67

565

142

1.00 (referent)

 

1.00 (referent)

 

 High KI67

436

107

1.75 (1.06–2.90)

0.028

1.70 (1.02–2.84)

0.044

T

  

0.86 (0.75–0.98)

0.031

0.86 (0.75–0.99)

0.031

HRN/HER2+ (HER2-enriched)

 Low KI67

227

85

1.00 (referent)

 

1.00 (referent)

 

 High KI67

149

48

0.76 (0.37–1.55)

0.450

0.75 (0.36–1.57)

0.455

T

  

1.08 (0.90–1.29)

0.396

1.07 (0.90–1.29)

0.435

  1. aPartially adjusted models—adjusted for age at diagnosis and study group
  2. bFully adjusted models—further adjustment for histological grade, tumour size, nodal status, morphology, PR, HER2, systemic therapy (endocrine and/or chemotherapy) and (for the model involving all patients) ER status. This model was based on 20 imputations performed to address missing values on other covariates
  3. cLog of time-varying coefficient (if T < 1 then hazard falls with time, and if T >1 then hazard increases with time)
  4. HRP hormone receptor-positive, HRN hormone receptor-negative, ER oestrogen receptor, HER2 human epidermal growth factor receptor 2, PR progesterone receptor